Guardian Pharmacy Services, Inc.

Fundamentals6.0
Price Action6.0
News Sentiment7.0
AI Rating
6.0

Key Drivers

  • High ROE
  • Solid Cash Flow
  • Rich Valuation

AI
AI Summary

6.0

GRDN looks more like a capital-efficient, acquisition-driven healthcare operator than a pure growth story, but with valuation already pricing in success, the key issue is whether improving margins and resident growth can overcome fragile quarterly cash conversion and integration risk.

AcquisitionGrowth
CashFlow
Healthcare‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

6.0

Key Financial Insights:

  • High ROE
  • Solid Cash Flow
  • Rich Valuation

GRDN delivers strong capital returns and solid full-year cash flow with manageable leverage, but its expensive valuation and weak recent-quarter cash conversion temper the investment case.

profitable
overvalued

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Rebound strength
  • Key support hold
  • Resistance ceiling

Over the last month, GRDN has rebounded to the top of its range, but it still needs to hold above $40.5 and break $43.4 to confirm further upside.

bullish
watchlist
Support Level: $40.4–$40.8
Resistance Level: $43.1–$43.4

Sharp late-June drop into the high-$38s followed by a quick rebound above $42

Sentiment & News

7.0

Key News Insights:

  • New-high momentum
  • Leadership transition
  • Virginia expansion

GRDN is showing strong stock momentum as it hits new highs and surges on volume, while leadership changes and a Virginia acquisition point to continued operational expansion despite some earnings pressure.

Growth
GRDN

The news is modestly positive overall, supporting investor interest through growth initiatives and share strength, though near-term upside may be limited by valuation and earnings revision concerns